PubMedBiomarker research2026-11-19
Irbesartan-loaded cRGD-modified PLGA nanoparticles attenuate intervertebral disc degeneration through an FGFR1-related mechanism.
Yu Xiao-Jun XJ, Wang Ying-Guang YG, Wang Shan-Xi SX, Li Ling-Jiang LJ et al.
Intervertebral disc degeneration (IDD) lacks effective disease-modifying therapy. This study evaluated the protective effects of irbesartan (Ir), explored fibroblast growth factor receptor 1 (FGFR1) as a candidate molecular mediator, and assessed whether cRGD modification could enhance nanoparticle uptake and local treatment effects.
Rat IDD models and IL-1β-induced degenerative nucleus pulposus cells were used to assess free Ir and Ir-loaded cRGD-modified PLGA nanoparticles (cRGD-NPs@Ir). Bioinformatics screening, cellular thermal shift assay (CETSA), and molecular docking were used to nominate FGFR1 as a candidate Ir-associated protein, and FGFR1 knockdown was used to test whether FGFR1 status modified the treatment response. Imaging, histology, immunohistochemistry, Western blotting, RT-qPCR, nanoparticle characterization, Coumarin-6 uptake assays, and tandem LC3 reporter analysis were used to evaluate treatment-associated changes.
Ir attenuated structural and molecular features of IDD, reduced MAPK/NF-κB signaling, altered autophagy-associated markers, and preserved extracellular matrix homeostasis. FGFR1 expression was lower in degenerative disc tissue, and FGFR1 knockdown attenuated several protective changes associated with Ir or cRGD-NPs@Ir. cRGD-NPs@Ir produced greater carrier-associated Coumarin-6 uptake than NPs@Ir and larger treatment-associated changes than free Ir for several directly compared endpoints. These findings support an FGFR1-related component of the response but do not establish direct Ir-FGFR1 binding, receptor-specific cRGD targeting, or exclusive FGFR1 dependence.
FGFR1 may contribute as a candidate molecular mediator to Ir-associated changes in autophagy and inflammatory signaling in IDD. cRGD-NPs@Ir provides an uptake-enhancing local nanodelivery strategy, although receptor specificity and direct Ir-FGFR1 binding require further validation.